10500-64-8
10500-64-8
Chemical Structure
Hydroxychloroquine Impurity E
Synonym(s): 4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol
- CAS No.: 10500-64-8
- Formula:C14H17ClN2O
- Molecular Weight:264.75
IUPAC Name: 4-((7-chloroquinolin-4-yl)amino)pentan-1-ol
InChIKey: BZUKCXDUDOUBKN-UHFFFAOYSA-N
SMILES: CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCO
Biological Activity: Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Hydroxychloroquine Impurity E | 99.83% | Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4 | 4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4 is the deuterium labeled Hydroxychloroquine Impurity E (HY-131262). Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6. [Content Brief]
- [2]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40. [Content Brief]
- [3]. Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. [Content Brief]
